

Marcin OpÅ,awski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6412787/publications.pdf>

Version: 2024-02-01

23
papers

146
citations

1307594

7
h-index

1281871

11
g-index

24
all docs

24
docs citations

24
times ranked

137
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2019, 20, 955-963.	1.6	17
2	Expression Pattern of Leptin and Its Receptors in Endometrioid Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 2787.	2.4	15
3	Identification of a gene expression profile associated with the regulation of angiogenesis in endometrial cancer. <i>Molecular Medicine Reports</i> , 2017, 16, 2547-2555.	2.4	13
4	Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2019, 20, 1004-1010.	1.6	13
5	Expression Profile of Endoglin in Different Grades of Endometrial Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2019, 19, 990-995.	1.6	10
6	Molecular Landscape of the Epithelial-Mesenchymal Transition in Endometrioid Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 1520.	2.4	9
7	Expression of Semaphorin 3B (SEMA3B) in Various Grades of Endometrial Cancer. <i>Medical Science Monitor</i> , 2019, 25, 4569-4574.	1.1	9
8	Assessment of the Usefulness of the SEMA5A Concentration Profile Changes as a Molecular Marker in Endometrial Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2020, 21, 45-51.	1.6	8
9	Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2020, 21, 52-59.	1.6	7
10	Salinomycin Modulates the Expression of mRNAs and miRNAs Related to Stemness in Endometrial Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, 317-326.	1.6	6
11	Effect of Salinomycin on Expression Pattern of Genes Associated with Apoptosis in Endometrial Cancer Cell Line. <i>Current Pharmaceutical Biotechnology</i> , 2020, 21, 1269-1277.	1.6	4
12	Variances in the Expression of mRNAs and miRNAs Related to the Histaminergic System in Endometrioid Endometrial Cancer. <i>Biomedicines</i> , 2021, 9, 1535.	3.2	4
13	miRNAs in the Expression Regulation of Dopamine-Related Genes and Proteins in Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 4939.	2.4	4
14	Functional Changes of the Genitourinary and Gastrointestinal Systems before and after the Treatment of Endometrial Cancer—A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 5579.	2.4	4
15	Assessment of Expression of Homeobox A5 in Endometrial Cancer on the mRNA and Protein Level. <i>Current Pharmaceutical Biotechnology</i> , 2020, 21, 635-641.	1.6	2
16	Assessment of Dysfunction in the Urinary System as Well as Comfort in the Life of Women during and after Combination Therapy Due to Ovarian and Endometrial Cancer Based on the SWL, II-Q7 and UDI-6 Scales. <i>Journal of Clinical Medicine</i> , 2021, 10, 1228.	2.4	2
17	The Influence of Salinomycin on the Expression Profile of mRNAs Encoding Selected Caspases and MiRNAs Regulating their Expression in Endometrial Cancer Cell Line. <i>Current Pharmaceutical Biotechnology</i> , 2020, 21, 1505-1515.	1.6	2
18	Evaluation of the Differences in the Expression of Biogenic Amine-Related mRNAs and Proteins in Endometrioid Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 4872.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Cisplatin Changes Expression of SEMA3B in Endometrial Cancer. Current Pharmaceutical Biotechnology, 2020, 21, 1368-1376.	1.6	2
20	The Impact of Surgical Treatment with Adjuvant Chemotherapy for Ovarian Cancer on Disorders in the Urinary System and Quality of Life in Women. Journal of Clinical Medicine, 2022, 11, 1300.	2.4	2
21	Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect. Current Pharmaceutical Biotechnology, 2021, 22, 697-705.	1.6	1
22	The impact of combination therapy for ovarian carcinoma on the urinary tract. Current Gynecologic Oncology, 2015, 13, 217-223.	0.1	1
23	An assessment of the urinary function and the comfort of life in patients after endometrial cancer combined treatment. Current Gynecologic Oncology, 2015, 13, 78-84.	0.1	1